文献速递前列腺癌

高强度聚焦超声半腺消融治疗前列腺癌:美国系列初步结果

High Intensity Focused Ultrasound Hemigland Ablation for Prostate Cancer: Initial Outcomes of a United States Series.
PubMed 文献 · J Urol · 2020-09-08

该研究连续纳入100例接受半腺高强度聚焦超声(HIFU)作为局限性前列腺癌初始治疗的患者,中位随访20个月,2年无治疗失败生存率为73%,无≥GG2复发、重复局灶HIFU和根治性治疗的生存率分别为76%、90%和91%。双侧前列腺癌是≥GG2复发的唯一预测因素(p=0.03),100%患者保持控尿,IIEF-5和I-PSS无显著差异。

要点

  • 半腺HIFU短期肿瘤控制可接受,2年避免根治治疗率达91%。
  • 双侧前列腺癌是术后≥GG2复发的唯一预测因素(p=0.03)。
  • 100%患者维持零垫控尿,勃起功能无显著变化。

核心结论

  • 半腺HIFU短期安全性好,勃起功能和控尿保留极佳,短期肿瘤控制可接受。
  • 2年时91%患者避免根治性治疗。
  • 诊断时双侧前列腺癌患者≥GG2复发风险增加。

研究设计与样本

  • 主要终点为治疗失败,定义为随访活检≥Grade Group 2、根治性治疗、全身治疗、转移或前列腺癌特异性死亡。
  • 中位随访20个月。

主要发现

  • 2年无治疗失败生存率为73%,无≥GG2复发生存率为76%,无重复局灶HIFU生存率为90%,无根治性治疗生存率为91%。
  • 诊断时双侧前列腺癌是≥GG2复发的唯一预测因素(p=0.03)。
  • 58例接受治疗后活检,其中10例为野内≥GG2阳性,8例为野外≥GG2阳性。
  • 100%患者维持零垫控尿。
  • IIEF-5中位评分术前22 vs 术后21(p=0.99),I-PSS中位评分术前9 vs 术后6(p=0.005)。

关键数值与推荐

  • 治疗失败定义为随访活检≥Grade Group 2、根治性治疗、全身治疗、转移或前列腺癌特异性死亡。
  • 风险分组:极低危8%,低危20%,中危有利50%,中危不利17%,高危5%。

临床怎么用

  • 半腺HIFU可作为部分局限性前列腺癌患者的初始治疗选择,尤其关注保留勃起功能和控尿。
  • 诊断时双侧前列腺癌患者应告知≥GG2复发风险增加,需加强随访。

局限性

  • 短期随访(中位20个月),缺乏长期肿瘤控制数据。
  • 单中心、连续病例系列,无对照组。
  • 仅58例患者接受治疗后活检,活检率有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We report outcomes of hemigland high intensity focused ultrasound ablation as primary treatment for localized prostate cancer in the United States. MATERIALS AND METHODS: A total of 100 consecutive men underwent hemigland high intensity focused ultrasound (December 2015 to December 2019). Primary end point was treatment failure, defined as Grade Group 2 or greater on followup prostate biopsy, radical treatment, systemic therapy, metastases or prostate cancer specific mortality. IIEF (International Index of Erectile Function), I-PSS (International Prostate Symptom Score) and 90-day complications were reported. RESULTS: At study entry patients had very low (8%), low (20%), intermediate favorable (50%), intermediate unfavorable (17%) and high (5%) risk prostate cancer. Median followup was 20 months. The 2-year survival free from treatment failure, Grade Group 2 or greater recurrence, repeat focal high intensity focused ultrasound and radical treatment was 73%, 76%, 90% and 91%, respectively. Bilateral prostate cancer at diagnosis was the sole predictor for Grade Group 2 or greater recurrence (p=0.03). Of men who underwent posttreatment biopsy (58), 10 had in-field and 8 out-of-field Grade Group 2 or greater positive biopsy. Continence (zero pad) was maintained in 100% of patients. Median IIEF-5 and I-PSS scores before vs after hemigland high intensity focused ultrasound were 22 vs 21 (p=0.99) and 9 vs 6 (p=0.005), respectively. Minor and major complications occurred in 13% and 0% of patients. No patient had rectal fistula or died. CONCLUSIONS: Short-term results of focal high intensity focused ultrasound indicate safety, excellent potency and continence preservation, and adequate short-term prostate cancer control. Radical treatment was avoided in 91% of men at 2 years. Men with bilateral prostate cancer at diagnosis have increased risk for Grade Group 2 or greater recurrence. To our knowledge, this is the initial and largest United States series of focal high intensity focused ultrasound as primary treatment for prostate cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Abreu AL, Peretsman S, Iwata A, et al. High Intensity Focused Ultrasound Hemigland Ablation for Prostate Cancer: Initial Outcomes of a United States Series. J Urol. 2020. PMID: 32898975. doi:10.1097/JU.0000000000001126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。